vinflunine and best supportive care

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Transitional Cell Carcinoma of the Urothelial Tract

Conditions

Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms

Trial Timeline

Jul 1, 2005 → Jan 1, 2008

NCT ID

NCT00315237

About vinflunine and best supportive care

vinflunine and best supportive care is a phase 3 stage product being developed by Bristol Myers Squibb for Transitional Cell Carcinoma of the Urothelial Tract. The current trial status is completed. This product is registered under clinical trial identifier NCT00315237. Target conditions include Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms.

What happened to similar drugs?

0 of 8 similar drugs in Transitional Cell Carcinoma of the Urothelial Tract were approved

Approved (0) Terminated (3) Active (5)

🔄Vepugratinib + EV + PembrolizumabEli LillyPhase 3

❌AtezolizumabRochePhase 3

🔄padeliporfin VTPICON plc.Phase 3

🔄UGN-101 instillationsUroGen PharmaPhase 3

🔄NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00315237	Phase 3	Completed	Jul 1, 2005	Jan 1, 2008	Transitional Cell Carcinoma of the Urothelial Tract

Competing Products

20 competing products in Transitional Cell Carcinoma of the Urothelial Tract

See all competitors

Product	Company	Stage	Hype Score
Enfortumab vedotin	Astellas Pharma	Phase 2	35
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine	Astellas Pharma	Phase 1/2	36
Pemetrexed + Gemcitabine + Platinol	Eli Lilly	Phase 1/2	32
Vepugratinib + EV + Pembrolizumab	Eli Lilly	Phase 3	47
durvalumab and tremelimumab	AstraZeneca	Phase 2	35
Docetaxel + vandetanib + Placebo	AstraZeneca	Phase 2	35
MK-3475 and BCG	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	31
Everolimus + Everolimus + Paclitaxel	Novartis	Phase 2	27
Buparlisib	Novartis	Phase 2	35
BEZ235	Novartis	Phase 2	27
Atezolizumab	Roche	Phase 3	32
Gemcitabine + Cisplatin + Sunitinib Malate	Pfizer	Phase 2	27
Nivolumab/Ipilimumab	Bristol Myers Squibb	Phase 2	31
vinflunine	Bristol Myers Squibb	Phase 2	35
Dasatinib	Bristol Myers Squibb	Pre-clinical	26
Docetaxel + Oxaliplatin	Sanofi	Phase 2	35
Cabazitaxel	Sanofi	Phase 2/3	38
Rogaratinib (BAY1163877) + Chemotherapy	Bayer	Phase 2/3	35
CG0070 Adenovirus Vector	CG Oncology	Phase 2/3	27